1. Core Composition & Physicochemical Specifications
| Item | Details |
| Formulation | Fixed - dose combination injectable: cagrilintide 2.4mg + semaglutide 2.4mg |
| Mechanism Class | Amylin analog + GLP - 1 receptor agonist (dual - target for weight control) |
| Administration | Once - weekly subcutaneous injection (abdomen, thigh, upper arm) |
| Dosage Regimen | Dose escalation over 16 weeks to maintenance (2.4mg/2.4mg); pre - filled pen |
| Stability | Store at 2 - 8°C; stable for 2 years unopened; avoid freezing/light |
| Solubility | Aqueous formulation; ready - to - use after reconstitution (pre - filled pen: no reconstitution needed) |
| Manufacturer | Novo Nordisk A/S (Denmark) |
| Regulatory Status | NDA submitted to FDA (Dec 2025); review ongoing (expected 2026 approval) |
2. Mechanism of Action
Cagrisema exerts synergistic weight - reducing effects via complementary pathways:
- GLP - 1 Receptor Activation (semaglutide): Delays gastric emptying, suppresses hypothalamic hunger signals, improves insulin sensitivity, and reduces post - prandial glucagon release.
- Amylin Receptor Activation (cagrilintide): Enhances satiety, reduces hedonic food cravings, regulates food intake, and synergizes with insulin to suppress post - prandial glucagon, complementing GLP - 1 actions.
- Synergistic Effects: Dual - receptor targeting amplifies weight loss, improves cardiometabolic risk markers (glycemia, lipids, blood pressure), and supports long - term weight maintenance beyond monotherapyNovo Nordisk Science Hub.
3. Efficacy & Clinical Applications
3.1 Core Clinical Outcomes (REDEFINE 1/2 Phase 3)
| Outcome | Cagrisema (2.4mg/2.4mg) | Semaglutide 2.4mg | Placebo |
| 68 - week Weight Loss (ITT) | 20.4% (22.7% with full adherence) | 12.9% | 3.0% |
| Weight Loss ≥5% Rate | 91.9% | ~85% | 31.5% |
| HbA1c Reduction | 1.8% (diabetes subgroup) | 1.5% | ~0.3% |
| Cardiometabolic Benefits | Reduced triglycerides, BP, hsCRP; improved HDLNovo Nordisk Science Hub | Moderate improvements | Minimal changes |
3.2 Clinical Applications
- Indications: Adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with ≥1 weight - related comorbidity (hypertension, type 2 diabetes, dyslipidemia), alongside calorie restriction and exercise.
- Key Advantages: Superior weight loss vs. GLP - 1 monotherapy; sustained efficacy for long - term weight maintenance; favorable safety/tolerability supporting chronic use.
4. Production & Quality Control
4.1 Manufacturing Process
- Peptide Synthesis: Solid - phase synthesis for cagrilintide and semaglutide; purification via RP - HPLC to ≥99% purity.
- Fixed - Dose Formulation: Precisely blend active ingredients; formulate as sterile aqueous solution for subcutaneous injection.
- Pre - filled Pen Assembly: Automated filling/sealing; quality testing ensures dose accuracy and sterility.
4.2 Quality Testing Standards
| Test Item | Specification | Detection Method |
| Peptide Purity | ≥99% (each component) | RP - HPLC |
| Content Uniformity | 95% - 105% of labeled dose | LC - MS |
| Endotoxin | ≤0.1 EU/mL | LAL test |
| Sterility | Aseptic | Membrane filtration |
| Stability | Stable at 2 - 8°C for 2 years | Accelerated stability testing |
5. Safety, Tolerability & Administration
5.1 Safety Profile
- Common Adverse Events (AEs): Mild - moderate gastrointestinal (nausea, diarrhea, vomiting, constipation); incidence ~60% - 70%, transient, resolving within 4 - 8 weeks.
- Rare AEs: Hypoglycemia (rare in non - diabetics); injection - site reactions (pain/redness, <5%); no new safety signals vs. GLP - 1 monotherapy.
- Contraindications: Hypersensitivity to cagrilintide/semaglutide; history of medullary thyroid carcinoma (MTC); multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Precautions: Monitor renal function in severe impairment; caution in pregnancy/lactation (limited data); adjust dose in elderly per tolerance.
5.2 Administration Guidelines
- Injection Route: Subcutaneous (abdomen preferred for absorption consistency).
- Dose Escalation: Start low, titrate every 4 weeks to maintenance (2.4mg/2.4mg) over 16 weeks to improve tolerability.
- Missed Dose: Administer within 5 days of scheduled dose; if >5 days, skip and resume next scheduled dose.
- Storage: Keep refrigerated (2 - 8°C); do not freeze; protect from light; discard 4 weeks after first use.
6. Advantages of Cagrisema
- First - in - Class Dual Mechanism: Combines amylin and GLP - 1 pathways for enhanced weight loss beyond monotherapy.
- Superior Efficacy: Phase 3 data show ~20% weight loss, exceeding GLP - 1 monotherapy benchmarks.
- Convenient Dosing: Once - weekly injection improves patient adherence vs. daily therapies.
- Cardiometabolic Benefits: Improves multiple risk factors (glycemia, lipids, BP) alongside weight lossNovo Nordisk Science Hub.
- Well - Tolerated: Safety profile aligns with GLP - 1 agents, enabling long - term use for chronic weight management.
Research & Reference Note
Cagrisema (2.5mg+2.5mg) is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Disclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals
China
